2-propanol has been researched along with Retinal Vein Occlusion in 82 studies
2-Propanol: An isomer of 1-PROPANOL. It is a colorless liquid having disinfectant properties. It is used in the manufacture of acetone and its derivatives and as a solvent. Topically, it is used as an antiseptic.
propan-2-ol : A secondary alcohol that is propane in which one of the hydrogens attached to the central carbon is substituted by a hydroxy group.
Retinal Vein Occlusion: Blockage of the RETINAL VEIN. Those at high risk for this condition include patients with HYPERTENSION; DIABETES MELLITUS; ATHEROSCLEROSIS; and other CARDIOVASCULAR DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion with that of aspirin." | 9.13 | Long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion. ( Farahvash, MM; Farahvash, MS; Mohammadzadeh, S; Moradimogadam, M, 2008) |
| "The clinical and histopathologic features of 29 eyes from 28 patients with central retinal vein occlusion (CRVO) are reported." | 7.66 | Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. ( Chan, CC; Green, WR; Hutchins, GM; Terry, JM, 1981) |
| "Triamcinolone acetonide (TA) has applications for the treatment of a large range of intraocular vascular diseases." | 5.37 | Intravitreal triamcinolone acetonide induced changes in the anterior segment in a pig model of branch retinal vein occlusion. ( Cringle, SJ; McAllister, IL; McMenamin, PG; Mendis, KR; Morgan, WH; Vijayasekaran, S; Yu, DY, 2011) |
| "To compare the long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion with that of aspirin." | 5.13 | Long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion. ( Farahvash, MM; Farahvash, MS; Mohammadzadeh, S; Moradimogadam, M, 2008) |
| "Photodynamic therapy using chloroaluminum sulfonated phthalocyanine (CASPc) effectively closed experimental iris neovascularization induced in 6 eyes of cynomolgus monkeys by argon laser retinal vein occlusion." | 3.68 | Phthalocyanine photodynamic therapy of experimental iris neovascularization. ( el-Koumy, HA; Gregory, WA; Miller, JW; Puliafito, CA; Stinson, WG, 1991) |
| "The clinical and histopathologic features of 29 eyes from 28 patients with central retinal vein occlusion (CRVO) are reported." | 3.66 | Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. ( Chan, CC; Green, WR; Hutchins, GM; Terry, JM, 1981) |
| "Intraocular pressure was significantly (P < 0." | 2.70 | Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. ( Hayler, JK; Jonas, JB; Panda-Jonas, S; Söfker, A, 2001) |
| "Neovascular glaucoma is defined as an iris and/or anterior chamber angle neovascularization associated with increased intraocular presure." | 2.48 | [Neovascular glaucoma--etipathogeny and diagnosis]. ( Călugăru, D; Călugăru, M, 2012) |
| "Triamcinolone acetonide (TA) has applications for the treatment of a large range of intraocular vascular diseases." | 1.37 | Intravitreal triamcinolone acetonide induced changes in the anterior segment in a pig model of branch retinal vein occlusion. ( Cringle, SJ; McAllister, IL; McMenamin, PG; Mendis, KR; Morgan, WH; Vijayasekaran, S; Yu, DY, 2011) |
| "Sixteen patients with ischemic central retinal vein occlusion were followed up for 12 months by clinical examination, retinal and iris angiography, and serial anterior chamber sampling of aqueous humor." | 1.31 | Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. ( Allen, GJ; Boyd, SR; Chakravarthy, U; Cree, IA; Hykin, PG; Martin, JF; Wisdom, GB; Zachary, I, 2002) |
| "Seven patients with central retinal vein occlusion were examined with full-field ERG within less than 24 hours after the onset of their symptoms and every second to third day during the first 3 weeks." | 1.31 | The 30-Hz flicker cone ERG for monitoring the early course of central retinal vein occlusion. ( Andréasson, S; Bauer, B; Larsson, J, 2000) |
| "44 patients with a central retinal vein occlusion were examined with full field electroretinogram (ERG)." | 1.31 | Photopic 30 Hz flicker ERG as a predictor for rubeosis in central retinal vein occlusion. ( Andréasson, S; Larsson, J, 2001) |
| "Results showed that recurrence of RVO in the same or fellow eye was decreased by more than half in the follow-up group (3." | 1.31 | Nine year follow-up study of morbidity and mortality in retinal vein occlusion. ( Dodson, PM; Kirwan, J; Kritzinger, EE; O'Leary, MB; Prior, P; Tsaloumas, MD; Vinall, H, 2000) |
| "In the management of cases of central retinal vein occlusion it is important to identify those patients who will develop the complication of iris neovascularisation." | 1.30 | Electroretinography of central retinal vein occlusion under scotopic and photopic conditions: what to measure? ( Bradnam, M; Keating, D; Williamson, TH, 1997) |
| "Data from a population of patients with central retinal vein occlusion were used to examine the ability of the derived parameters to predict the development of neovascularization of the iris." | 1.29 | The care and fitting of Naka-Rushton functions to electroretinographic intensity-response data. ( Johnson, MA; Severns, ML, 1993) |
| "We conclude that neovascular glaucoma is more likely to occur in older subjects with CRVO." | 1.29 | Are there medical conditions specifically underlying the development of rubeosis in central retinal vein occlusion? ( Dodson, PM; Keenan, JM; Kritzinger, EE, 1993) |
| "Laser retinal vein occlusion was used to produce retinal ischemia in 16 eyes of eight animals (Macaca fascicularis)." | 1.29 | Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. ( Adamis, AP; D'Amore, PA; Ferrara, N; Folkman, J; Gragoudas, ES; Miller, JW; Shima, DT; Tolentino, MJ, 1996) |
| "We report a case of central retinal vein occlusion presenting several capillary macroaneurysms." | 1.29 | Capillary macroaneurysms in central retinal vein occlusion. ( Battaglia Parodi, M; Bondel, E; Ravalico, G, 1995) |
| "Patients with central retinal vein occlusion who later develop iris neovascularization show changes in the amplitude, the timing, and the sensitivity of the electroretinogram beta wave." | 1.29 | Rod photoreceptor transduction is affected in central retinal vein occlusion associated with iris neovascularization. ( Hood, DC; Johnson, MA, 1996) |
| "In five of the seven patients, the retinal hemorrhages appeared most florid in the territory of the obstructed arteriole, resulting initially in the consideration that these cases represented a combined branch retinal artery and branch retinal vein obstruction." | 1.28 | Combined branch retinal artery and central retinal vein obstruction. ( Brown, GC; Cohen, MS; Duker, JS; McNamara, JA; Sergott, RC, 1990) |
| "Twenty seven eyes treated for ischaemic central retinal vein occlusion with panretinal photocoagulation were reviewed." | 1.28 | Neovascular response in ischaemic central retinal vein occlusion after panretinal photocoagulation. ( Murdoch, IE; Rosen, PH; Shilling, JS, 1991) |
| "The two types of central retinal vein occlusion, and suggestions for their management, are also discussed." | 1.27 | Central retinal vein occlusion and iris neovascularization hemorrhage. ( Lalle, PA; Myers, KJ, 1988) |
| "Intraocular pressure was reduced from a mean of 35." | 1.27 | [Retinal cryocoagulation in rubeosis iridis]. ( Schildwächter, A; Witschel, H, 1988) |
| "A 32-year-old man with central retinal vein occlusion followed by severe and rapidly progressing neo-vascular glaucoma is presented." | 1.27 | Severe ischemic process in a young man with central retinal vein occlusion. ( Chen, V; Moisseiev, J; Treister, G, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (14.63) | 18.7374 |
| 1990's | 34 (41.46) | 18.2507 |
| 2000's | 21 (25.61) | 29.6817 |
| 2010's | 12 (14.63) | 24.3611 |
| 2020's | 3 (3.66) | 2.80 |
| Authors | Studies |
|---|---|
| Sim, HE | 1 |
| Hwang, JH | 1 |
| Reddy, PRR | 1 |
| Singh, DV | 1 |
| Baharani, A | 1 |
| Senthil, S | 1 |
| Dada, T | 1 |
| Das, T | 1 |
| Kaushik, S | 1 |
| Puthuran, GV | 1 |
| Philip, R | 1 |
| Rani, PK | 1 |
| Rao, H | 1 |
| Singla, S | 1 |
| Vijaya, L | 1 |
| McLeod, D | 1 |
| Călugăru, D | 1 |
| Călugăru, M | 1 |
| Gandhi, JS | 1 |
| Md Noh, UK | 1 |
| Ahem, A | 1 |
| Mustapha, M | 1 |
| McAllister, IL | 2 |
| Tan, MH | 1 |
| Smithies, LA | 1 |
| Wong, WL | 1 |
| Mohammadi, M | 1 |
| Bazvand, F | 1 |
| Makateb, A | 1 |
| Eslami, Y | 1 |
| Jabbarvand Behrooz, M | 1 |
| Fakhraie, G | 1 |
| Zarei, R | 1 |
| Moghimi, S | 1 |
| Farahvash, MS | 1 |
| Farahvash, MM | 1 |
| Moradimogadam, M | 1 |
| Mohammadzadeh, S | 1 |
| Jonas, JB | 2 |
| Libondi, T | 1 |
| Schlichtenbrede, F | 1 |
| Schmidbauer, M | 1 |
| Vijayasekaran, S | 1 |
| Morgan, WH | 1 |
| Mendis, KR | 1 |
| McMenamin, PG | 1 |
| Cringle, SJ | 1 |
| Yu, DY | 1 |
| Verdaguer, P | 1 |
| Verdaguer Agustí, P | 1 |
| Nadal Reus, J | 1 |
| George, MK | 1 |
| Tsai, JC | 1 |
| Loewen, NA | 1 |
| Chan, CK | 1 |
| Ip, MS | 1 |
| Vanveldhuisen, PC | 1 |
| Oden, NL | 1 |
| Scott, IU | 1 |
| Tolentino, MJ | 2 |
| Blodi, BA | 1 |
| Joshi, L | 1 |
| Tomkins-Netzer, O | 1 |
| Menezo, V | 1 |
| Sallam, A | 1 |
| Kirkpatrick, N | 1 |
| Lightman, S | 1 |
| Taylor, SR | 1 |
| Boyd, SR | 1 |
| Zachary, I | 1 |
| Chakravarthy, U | 1 |
| Allen, GJ | 1 |
| Wisdom, GB | 1 |
| Cree, IA | 1 |
| Martin, JF | 1 |
| Hykin, PG | 1 |
| Genaidy, M | 1 |
| Kazi, AA | 1 |
| Peyman, GA | 1 |
| Passos-Machado, E | 1 |
| Farahat, HG | 1 |
| Williams, JI | 1 |
| Holroyd, KJ | 1 |
| Blake, DA | 1 |
| Hayreh, SS | 3 |
| Fuller, JJ | 1 |
| Mason, JO | 1 |
| White, MF | 1 |
| McGwin, G | 1 |
| Emond, TL | 1 |
| Feist, RM | 1 |
| Elgohary, MA | 1 |
| Sheldrick, JH | 1 |
| Paques, M | 1 |
| Girmens, JF | 1 |
| Rivière, E | 1 |
| Sahel, J | 1 |
| Green, WR | 1 |
| Chan, CC | 1 |
| Hutchins, GM | 1 |
| Terry, JM | 1 |
| Bhisitkul, RB | 1 |
| Robinson, GS | 1 |
| Moulton, RS | 1 |
| Claffey, KP | 1 |
| Gragoudas, ES | 2 |
| Miller, JW | 5 |
| Ramezani, A | 1 |
| Entezari, M | 1 |
| Moradian, S | 1 |
| Tabatabaei, H | 1 |
| Kadkhodaei, S | 1 |
| Grisanti, S | 1 |
| Biester, S | 1 |
| Peters, S | 1 |
| Tatar, O | 1 |
| Ziemssen, F | 1 |
| Bartz-Schmidt, KU | 1 |
| Löffler, KU | 1 |
| Iliev, ME | 1 |
| Domig, D | 1 |
| Wolf-Schnurrbursch, U | 1 |
| Wolf, S | 1 |
| Sarra, GM | 1 |
| Madhusudhana, KC | 1 |
| Newsom, RS | 1 |
| Batioğlu, F | 1 |
| Astam, N | 1 |
| Ozmert, E | 1 |
| Lang, GE | 2 |
| Parodi, MB | 1 |
| Iacono, P | 1 |
| Ravalico, G | 2 |
| Williamson, TH | 5 |
| Baxter, GM | 1 |
| Severns, ML | 2 |
| Johnson, MA | 5 |
| Clarkson, JG | 1 |
| Stefaniotou, M | 1 |
| Paschides, CA | 1 |
| Psilas, K | 1 |
| Maruyama, Y | 1 |
| Kishi, S | 1 |
| Kamei, Y | 1 |
| Shimizu, R | 1 |
| Kimura, Y | 1 |
| Stinson, WG | 2 |
| Folkman, J | 2 |
| McPhee, TJ | 2 |
| Brown, GC | 3 |
| Duker, JS | 2 |
| Lehman, R | 1 |
| Eagle, RC | 1 |
| Keenan, JM | 1 |
| Dodson, PM | 2 |
| Kritzinger, EE | 2 |
| Adamis, AP | 2 |
| Shima, DT | 2 |
| Ferrara, N | 1 |
| D'Amore, PA | 2 |
| Ramsay, A | 1 |
| Parks, S | 1 |
| Keating, D | 2 |
| Battaglia Parodi, M | 1 |
| Bondel, E | 1 |
| Hood, DC | 1 |
| Gougos, A | 1 |
| Tolentino, M | 1 |
| Robinson, G | 1 |
| Rumley, A | 1 |
| Lowe, GD | 1 |
| Luckie, AP | 1 |
| Wroblewski, JJ | 1 |
| Bird, AC | 1 |
| Hamilton, AM | 1 |
| Sanders, MD | 1 |
| Green, W | 1 |
| Slater, NG | 1 |
| Bradnam, M | 1 |
| Lindblom, B | 1 |
| Browning, DJ | 1 |
| Scott, AQ | 1 |
| Peterson, CB | 1 |
| Warnock, J | 1 |
| Zhang, Z | 1 |
| Shah, GK | 1 |
| Sharma, S | 1 |
| Chen, KH | 1 |
| Wu, CC | 1 |
| Roy, S | 1 |
| Lee, SM | 1 |
| Liu, JH | 1 |
| Larsson, J | 2 |
| Bauer, B | 1 |
| Andréasson, S | 2 |
| Nahberger, D | 1 |
| Meyer-Schwickerath, R | 1 |
| Saygili, O | 1 |
| Gronemeyer, U | 1 |
| Hayler, JK | 1 |
| Söfker, A | 1 |
| Panda-Jonas, S | 1 |
| Tsaloumas, MD | 1 |
| Kirwan, J | 1 |
| Vinall, H | 1 |
| O'Leary, MB | 1 |
| Prior, P | 1 |
| Brooks, AM | 1 |
| Gillies, WE | 1 |
| Klugman, MR | 1 |
| Podhajsky, P | 1 |
| Servais, GE | 1 |
| Perkins, ES | 1 |
| Cohen, MS | 1 |
| Sergott, RC | 1 |
| McNamara, JA | 1 |
| Barke, RM | 1 |
| Yoshizumi, MO | 1 |
| Hepler, RS | 1 |
| Krauss, HR | 1 |
| Jabour, BA | 1 |
| Murdoch, IE | 1 |
| Rosen, PH | 1 |
| Shilling, JS | 1 |
| Breton, ME | 2 |
| Schueller, AW | 1 |
| Montzka, DP | 1 |
| Gregory, WA | 1 |
| el-Koumy, HA | 1 |
| Puliafito, CA | 1 |
| Terry, JE | 1 |
| Roberts, DK | 1 |
| Welge-Lüssen, L | 1 |
| Stadler, G | 1 |
| Bresnick, GH | 1 |
| Marcus, S | 1 |
| Elman, MJ | 1 |
| Kaye, SB | 1 |
| Harding, SP | 1 |
| Trempe, CL | 1 |
| Myers, KJ | 1 |
| Lalle, PA | 1 |
| Schildwächter, A | 1 |
| Witschel, H | 1 |
| Nork, TM | 1 |
| Tso, MO | 1 |
| Duvall, J | 1 |
| Quinn, GE | 1 |
| Keene, SS | 1 |
| Dahmen, JC | 1 |
| Brucker, AJ | 1 |
| Chen, V | 1 |
| Moisseiev, J | 1 |
| Treister, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema[NCT00105027] | Phase 3 | 682 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Phase IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects [NCT01710839] | Phase 4 | 30 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Pilot Study for the Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab Avastin or Ranibizumab Lucentis[NCT00605943] | 30 participants | Observational | 2008-01-16 | Completed | |||
| Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment[NCT00548197] | Phase 1 | 40 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Randomized Controlled Trial of Lucentis in the Management of New Onset Neovascular Glaucoma[NCT00727038] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2008-01-04 | Withdrawn (stopped due to Company withdrew funding/sponsorship) | ||
| [NCT00000131] | Phase 3 | 0 participants | Interventional | 1988-08-31 | Completed | ||
| The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study[NCT00106132] | Phase 3 | 1,260 participants | Interventional | 2005-03-31 | Completed | ||
| Ultra-wide Fluorescein angiograpHy to Evaluate the Progression of Retinal ischeMia After aflibErcept Injections in patientS With Central Retinal Vein Occlusion in Real Life (HERMES Study)[NCT02880644] | 65 participants (Actual) | Observational [Patient Registry] | 2017-01-26 | Completed | |||
| Correlation Between the Visual Acuity and the OCT Pattern of Macular Edema Secondary to Retinal Vein Occlusion[NCT03489915] | 30 participants (Anticipated) | Observational | 2018-05-01 | Not yet recruiting | |||
| Uncovering Inflammatory Mediators of Glaucoma Pathogenesis After Corneal Transplantation in Aqueous Humor and Tears[NCT04339907] | 200 participants (Anticipated) | Interventional | 2020-05-11 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00105027)
Timeframe: 12 months
| Intervention | letters read (Mean) |
|---|---|
| CRVO Observation | -12.1 |
| CRVO 1 mg Dose Triamcinolone Acetonide | -1.2 |
| CRVO 4 mg Dose Triamcinolone Acetonide | -1.2 |
| BRVO Standard Care | 4.2 |
| BRVO 1 mg Dose Triamcinolone Acetonide | 5.7 |
| BRVO 4 mg Dose Triamcinolone Acetonide | 4.0 |
(NCT00105027)
Timeframe: 12 months
| Intervention | um (Median) |
|---|---|
| CRVO Observation | -277 |
| CRVO 1 mg Dose Triamcinolone Acetonide | -196 |
| CRVO 4 mg Dose Triamcinolone Acetonide | -261 |
| BRVO Standard Care | -224 |
| BRVO 1 mg Dose Triamcinolone Acetonide | -149 |
| BRVO 4 mg Dose Triamcinolone Acetonide | -170 |
Visual acuity testing was done using electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity testing at 3 meters using the Electronic Visual Acuity Tester by a SCORE certified technician. A masked visual acuity examiner with no knowledge of treatment assignments performed visual acuity testing at the 4-month, 12-month, 24-month and 36-month visits. An E-ETDRS visual acuity score of 85 is approximately 20/20, and a score of 20 letters is approximately 20/400. A visual acuity letter score change of 15 is about three lines on a vision chart. (NCT00105027)
Timeframe: Change from baseline to 12 months
| Intervention | Participants (Number) |
|---|---|
| CRVO Observation | 5 |
| CRVO 1 mg Dose Triamcinolone Acetonide | 22 |
| CRVO 4 mg Dose Triamcinolone Acetonide | 21 |
| BRVO Standard Care | 35 |
| BRVO 1 mg Dose Triamcinolone Acetonide | 31 |
| BRVO 4 mg Dose Triamcinolone Acetonide | 34 |
(NCT00105027)
Timeframe: 12 months
| Intervention | events (Number) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Initiation of IOP-lowering medications | IOP > 35 mm HG | IOP > 10 mm HG above baseline | Laser peripheral iridotomy | Trabeculectomy | Tube shunt | Cataract: lens opacity onset or progression | Cataract surgery | Infectious endophthalmitis | Noninfectious endophthalmitis | Retinal detachment | Iris neovascularization | Retinal neovascularization | Vitreous hemorrhage | YAG capsulotomy | Sector or panretinal photocagulation | Pars plana vitrectomy | |
| BRVO 1 mg Dose Triamcinolone Acetonide | 11 | 2 | 12 | 0 | 0 | 0 | 27 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 |
| BRVO 4 mg Dose Triamcinolone Acetonide | 57 | 14 | 50 | 1 | 0 | 0 | 38 | 4 | 1 | 0 | 0 | 2 | 3 | 3 | 1 | 4 | 1 |
| BRVO Standard Care | 3 | 1 | 1 | 0 | 0 | 0 | 15 | 3 | 0 | 0 | 1 | 1 | 5 | 2 | 1 | 5 | 1 |
| CRVO 1 mg Dose Triamcinolone Acetonide | 18 | 5 | 15 | 0 | 0 | 2 | 20 | 0 | 0 | 0 | 0 | 9 | 2 | 4 | 0 | 9 | 2 |
| CRVO 4 mg Dose Triamcinolone Acetonide | 32 | 8 | 24 | 1 | 0 | 0 | 25 | 4 | 0 | 0 | 0 | 4 | 2 | 0 | 0 | 3 | 0 |
| CRVO Observation | 7 | 1 | 2 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 2 | 4 | 4 | 1 | 5 | 1 |
Mean change in Central Foveal Volume on High Resolution OCT. (NCT01710839)
Timeframe: 12 months
| Intervention | cubic millimeters (Mean) |
|---|---|
| Targeted Pan Retinal Laser Combined With 0.5mg Ranibizumab | -0.15 |
| Ranibizumab 0.5mg | -0.15 |
Percent of patients that develop neovascularization of the iris, optic nerve and/or elsewhere. (NCT01710839)
Timeframe: 12 months
| Intervention | percentage of patients (Number) |
|---|---|
| Targeted Pan Retinal Laser Combined With 0.5mg Ranibizumab | 8.33 |
| Ranibizumab 0.5mg | 0 |
Assess the number of intravitreal injections over 12 months. (NCT01710839)
Timeframe: 12 months
| Intervention | injections (Mean) |
|---|---|
| Targeted Pan Retinal Laser Combined With 0.5mg Ranibizumab | 8.7 |
| Ranibizumab 0.5mg | 9.5 |
Evaluate the mean change from baseline in ETDRS best-corrected visual acuity at 12 months. The ETDRS protocol is a widely accepted international standard for macular laser photocoagulation treatment. A higher score represents better functioning. (NCT01710839)
Timeframe: 12 month period
| Intervention | ETDRS BCVA Letters (Mean) |
|---|---|
| Targeted Pan Retinal Laser Combined With 0.5mg Ranibizumab | 14.9 |
| Ranibizumab 0.5mg | 10.7 |
Incidence and severity of adverse events (ocular and non-ocular). (NCT01710839)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Notable Ocular Events | Serious Non-Ocular Events | |
| Ranibizumab 0.5mg | 2 | 0 |
| Targeted Pan Retinal Laser Combined With 0.5mg Ranibizumab | 17 | 2 |
Goldman Visual Field changes at 6 and 12 months from baseline. Goldmann perimetry is a method used to map a patient's field of vision (central and peripheral). Changes will be assessed by manual digital quantification of GVF plots. (NCT01710839)
Timeframe: 6 and 12 Months
| Intervention | square degrees (Mean) | |
|---|---|---|
| Month 6 | Month 12 | |
| Ranibizumab 0.5mg | 102 | -1875 |
| Targeted Pan Retinal Laser Combined With 0.5mg Ranibizumab | -1269 | -1628 |
Number of Participants with Postoperative Vitreous Hemorrhage (NCT00548197)
Timeframe: Last follow up, an average of 7 months post-operation
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Group | 0 |
| Control Group | 7 |
Post operative best corrected visual acuity ( best distance vision with eyeglasses or contact lenses) (NCT00548197)
Timeframe: last follow up, an average of 7 months post-operation
| Intervention | LogMar (Mean) |
|---|---|
| Intervention | 1.1 |
| Control | 1.4 |
3 reviews available for 2-propanol and Retinal Vein Occlusion
| Article | Year |
|---|---|
Neovascular glaucoma - A review.
Topics: Diabetic Retinopathy; Glaucoma, Neovascular; Humans; Intraocular Pressure; Iris; Retinal Diseases; R | 2021 |
[Neovascular glaucoma--etipathogeny and diagnosis].
Topics: Arterial Occlusive Diseases; Diabetic Retinopathy; Diagnosis, Differential; Eye; Eye Neoplasms; Glau | 2012 |
Central retinal vein occlusion: what's the story?
Topics: Arteriosclerosis; Humans; Iris; Neovascularization, Pathologic; Retinal Vein Occlusion; Risk Factors | 1997 |
Central retinal vein occlusion: what's the story?
Topics: Arteriosclerosis; Humans; Iris; Neovascularization, Pathologic; Retinal Vein Occlusion; Risk Factors | 1997 |
Central retinal vein occlusion: what's the story?
Topics: Arteriosclerosis; Humans; Iris; Neovascularization, Pathologic; Retinal Vein Occlusion; Risk Factors | 1997 |
Central retinal vein occlusion: what's the story?
Topics: Arteriosclerosis; Humans; Iris; Neovascularization, Pathologic; Retinal Vein Occlusion; Risk Factors | 1997 |
10 trials available for 2-propanol and Retinal Vein Occlusion
| Article | Year |
|---|---|
Long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion.
Topics: Aspirin; Dalteparin; Female; Fibrinolytic Agents; Humans; Iris; Male; Middle Aged; Neovascularizatio | 2008 |
SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.
Topics: Aged; Capillaries; Female; Glaucoma, Neovascular; Glucocorticoids; Humans; Incidence; Iris; Ischemia | 2011 |
Intravitreal triamcinolone for acute central retinal vein occlusion; a randomized clinical trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Female; Glucocorticoids; Humans; Injections; Intraocu | 2006 |
Central Vein Occlusion Study: photographic protocol and early natural history.
Topics: Fluorescein Angiography; Fundus Oculi; Humans; Iris; Laser Coagulation; Macular Edema; Neovasculariz | 1994 |
Baseline and early natural history report. The Central Vein Occlusion Study.
Topics: Adult; Aged; Aged, 80 and over; Edema; Female; Follow-Up Studies; Humans; Iris; Light Coagulation; M | 1993 |
Baseline and early natural history report. The Central Vein Occlusion Study.
Topics: Adult; Aged; Aged, 80 and over; Edema; Female; Follow-Up Studies; Humans; Iris; Light Coagulation; M | 1993 |
Baseline and early natural history report. The Central Vein Occlusion Study.
Topics: Adult; Aged; Aged, 80 and over; Edema; Female; Follow-Up Studies; Humans; Iris; Light Coagulation; M | 1993 |
Baseline and early natural history report. The Central Vein Occlusion Study.
Topics: Adult; Aged; Aged, 80 and over; Edema; Female; Follow-Up Studies; Humans; Iris; Light Coagulation; M | 1993 |
The venous closing pressure in central retinal vein obstruction.
Topics: Adult; Aged; Aged, 80 and over; Female; Fundus Oculi; Hemodilution; Humans; Intraocular Pressure; Ir | 1996 |
A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Fundus Oculi; Humans; Iris; Ischemia; Las | 1995 |
A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Fundus Oculi; Humans; Iris; Ischemia; Las | 1995 |
A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Fundus Oculi; Humans; Iris; Ischemia; Las | 1995 |
A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Fundus Oculi; Humans; Iris; Ischemia; Las | 1995 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.
Topics: Aged; Cohort Studies; Female; Glaucoma; Guidelines as Topic; Humans; Iris; Light Coagulation; Male; | 1997 |
Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone.
Topics: Aged; Aged, 80 and over; Crystallization; Diabetic Retinopathy; Female; Glaucoma, Neovascular; Gluco | 2001 |
Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study.
Topics: Aged; Analysis of Variance; Clinical Protocols; Data Interpretation, Statistical; Female; Glaucoma, | 1990 |
69 other studies available for 2-propanol and Retinal Vein Occlusion
| Article | Year |
|---|---|
Hyperacute iris neovascularization following cataract surgery.
Topics: Aged; Bevacizumab; Cataract; Humans; Iris; Macular Edema; Male; Neovascularization, Pathologic; Reti | 2022 |
Comments on: Retinal vein occlusion in COVID-19: A novel entity.
Topics: COVID-19; Humans; Iris; Lens Implantation, Intraocular; Retinal Vein Occlusion; SARS-CoV-2 | 2021 |
The Penumbra Obscura Stimulates Iris Neovascularisation after Isolated Central Retinal Artery Occlusion.
Topics: Humans; Iris; Neovascularization, Pathologic; Retinal Artery Occlusion; Retinal Vein Occlusion | 2017 |
Images in clinical medicine. Neovascular festoons on the iris.
Topics: Aged; Humans; Hypertension; Iris; Male; Neovascularization, Pathologic; Retinal Vein Occlusion | 2013 |
Bilateral retinal vein occlusion and rubeosis irides: lessons to learn.
Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Humans; Iris; Laser Coagulation; Neovascularizatio | 2013 |
The effect of central retinal venous pressure in patients with central retinal vein occlusion and a high mean area of nonperfusion.
Topics: Aged; Blood Pressure; Cohort Studies; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Ir | 2014 |
COMPARISON OF ANTERIOR SEGMENT OPTICAL COHERENCE TOMOGRAPHY PARAMETERS BETWEEN CENTRAL RETINAL VEIN OCCLUSION AND NORMAL EYES: Is Primary Angle Closure a Risk Factor for Central Retinal Vein Occlusion?
Topics: Aged; Anterior Eye Segment; Biometry; Case-Control Studies; Cross-Sectional Studies; Female; Glaucom | 2015 |
Intravitreal triamcinolone after intravitreal bevacizumab for retinal vein occlusions.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizuma | 2010 |
Intravitreal triamcinolone acetonide induced changes in the anterior segment in a pig model of branch retinal vein occlusion.
Topics: Animals; Anterior Eye Segment; Ciliary Body; Cytoskeletal Proteins; Disease Models, Animal; Eye Prot | 2011 |
[Long-term clinical outcome of radial optic neurotomy].
Topics: Aged; Cataract; Decompression, Surgical; Female; Follow-Up Studies; Humans; Intraocular Pressure; Ir | 2010 |
Bilateral irreversible severe vision loss from cosmetic iris implants.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Blindness; Device Rem | 2011 |
Dexamethasone implants and neovascular glaucoma in central retinal vein occlusion.
Topics: Dexamethasone; Drug Implants; Fluorescein Angiography; Glaucoma, Neovascular; Glucocorticoids; Gonio | 2013 |
Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion.
Topics: Adult; Aged; Aged, 80 and over; Aqueous Humor; Capillary Permeability; Electrophoresis, Capillary; E | 2002 |
Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion.
Topics: Adult; Aged; Aged, 80 and over; Aqueous Humor; Capillary Permeability; Electrophoresis, Capillary; E | 2002 |
Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion.
Topics: Adult; Aged; Aged, 80 and over; Aqueous Humor; Capillary Permeability; Electrophoresis, Capillary; E | 2002 |
Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion.
Topics: Adult; Aged; Aged, 80 and over; Aqueous Humor; Capillary Permeability; Electrophoresis, Capillary; E | 2002 |
Effect of squalamine on iris neovascularization in monkeys.
Topics: Angiogenesis Inhibitors; Animals; Cholestanols; Disease Models, Animal; Fluorescein Angiography; Inf | 2002 |
Evidence-based recommendations for neovascular glaucoma.
Topics: Evidence-Based Medicine; Glaucoma, Neovascular; Humans; Iris; Laser Coagulation; Practice Guidelines | 2003 |
Retinochoroidal collateral veins protect against anterior segment neovascularization after central retinal vein occlusion.
Topics: Aged; Aged, 80 and over; Anterior Eye Segment; Choroid; Collateral Circulation; Female; Fluorescein | 2003 |
Spontaneous hyphaema from pupillary vascular tufts in a patient with branch retinal vein occlusion.
Topics: Acute Disease; Aged; Female; Follow-Up Studies; Humans; Hyphema; Iris; Retinal Vein Occlusion | 2005 |
Dilation of the minor arterial circle of the iris preceding rubeosis iridis during retinal vein occlusion.
Topics: Aged; Arteries; Dilatation, Pathologic; Female; Fluorescein Angiography; Humans; Iris; Iris Diseases | 2004 |
Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Eye; Female; Humans; Infant; Iris; Macular Ede | 1981 |
An antisense oligodeoxynucleotide against vascular endothelial growth factor in a nonhuman primate model of iris neovascularization.
Topics: Animals; Disease Models, Animal; Fluorescein Angiography; Fluorescein-5-isothiocyanate; Genetic Ther | 2005 |
Intracameral bevacizumab for iris rubeosis.
Topics: Aged; Angiogenesis Inhibitors; Anterior Chamber; Antibodies, Monoclonal; Antibodies, Monoclonal, Hum | 2006 |
[Neovascular glaucoma: aetiology, pathogenesis and treatment].
Topics: Capillaries; Diabetic Retinopathy; Diagnosis, Differential; Eye Neoplasms; Glaucoma, Neovascular; Hu | 2006 |
Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2006 |
Central retinal vein occlusion: the therapeutic options.
Topics: Combined Modality Therapy; Fluorescein Angiography; Glaucoma, Neovascular; Humans; Iris; Macular Ede | 2007 |
Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Flu | 2008 |
[Central retinal vein occlusion].
Topics: Comorbidity; Epiretinal Membrane; Fluorescein Angiography; Follow-Up Studies; Humans; Iris; Neovascu | 2007 |
Verteporfin photodynamic therapy for anterior segment neovascularization secondary to ischaemic central retinal vein occlusion.
Topics: Aged; Anterior Eye Segment; Blood Vessels; Female; Fluorescein Angiography; Humans; Intraocular Pres | 2008 |
[Results of laser coagulation of central retinal vein occlusion].
Topics: Fluorescein Angiography; Follow-Up Studies; Glaucoma, Angle-Closure; Humans; Iris; Ischemia; Laser C | 1993 |
Central retinal vein occlusion, an investigation by color Doppler imaging. Blood velocity characteristics and prediction of iris neovascularization.
Topics: Adult; Aged; Aged, 80 and over; Blood Flow Velocity; Female; Humans; Iris; Ischemia; Male; Middle Ag | 1994 |
The care and fitting of Naka-Rushton functions to electroretinographic intensity-response data.
Topics: Adult; Aged; Algorithms; Diagnosis, Computer-Assisted; Electroretinography; Humans; Iris; Middle Age | 1993 |
Panretinal cryopexy for the management of neovascularization of the iris.
Topics: Aged; Cryosurgery; Diabetic Retinopathy; Female; Glaucoma, Neovascular; Humans; Iris; Iris Diseases; | 1995 |
Infrared angiography of the anterior ocular segment.
Topics: Adult; Aged; Anterior Eye Segment; Diabetic Retinopathy; Exfoliation Syndrome; Fluorescein; Fluoresc | 1995 |
Regression of experimental iris neovascularization with systemic alpha-interferon.
Topics: Animals; Disease Models, Animal; Fluorescein Angiography; Interferon alpha-2; Interferon-alpha; Iris | 1993 |
Electroretinographic findings in iris neovascularization due to acute central retinal vein occlusion.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Electroretinography; Follow-Up Studies; Humans; Iris; | 1993 |
Combined central retinal artery-central vein obstruction.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Hu | 1993 |
Predicting outcome in central retinal vein occlusion using the flicker electroretinogram.
Topics: Dark Adaptation; Electroretinography; Humans; Iris; Light; Neovascularization, Pathologic; Predictiv | 1993 |
Are there medical conditions specifically underlying the development of rubeosis in central retinal vein occlusion?
Topics: Adult; Age Factors; Aged; Cardiovascular Diseases; Diabetes Complications; Female; Glaucoma, Neovasc | 1993 |
Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate.
Topics: Animals; Antibodies, Monoclonal; Blotting, Northern; Capillary Permeability; Endothelial Growth Fact | 1996 |
Crossed polarising filters to measure relative afferent pupillary defects: reproducibility, correlation with neutral density filters and use in central retinal vein occlusion.
Topics: Adult; Aged; Aged, 80 and over; Female; Filtration; Humans; Iris; Light; Male; Middle Aged; Neovascu | 1995 |
Capillary macroaneurysms in central retinal vein occlusion.
Topics: Aged; Aneurysm; Capillaries; Female; Fluorescein Angiography; Fundus Oculi; Glaucoma, Neovascular; H | 1995 |
Rod photoreceptor transduction is affected in central retinal vein occlusion associated with iris neovascularization.
Topics: Adult; Aged; Aged, 80 and over; Electroretinography; Forecasting; Humans; Iris; Middle Aged; Neovasc | 1996 |
Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis.
Topics: Alternative Splicing; Amino Acid Sequence; Animals; Base Sequence; Blotting, Southern; Cloning, Mole | 1996 |
Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study.
Topics: Adult; Aged; Aged, 80 and over; Blood Coagulation; Blood Viscosity; Case-Control Studies; Female; Hu | 1996 |
Electroretinography of central retinal vein occlusion under scotopic and photopic conditions: what to measure?
Topics: Adaptation, Ocular; Adult; Aged; Aged, 80 and over; Dark Adaptation; Electroretinography; Female; Hu | 1997 |
Fluorescein angiography of the iris in the management of eyes with central retinal vein occlusion.
Topics: Adult; Aged; Fluorescein Angiography; Glaucoma; Humans; Intraocular Pressure; Iris; Iris Diseases; L | 1998 |
The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion.
Topics: Acute Disease; Adult; Aged; Anterior Eye Segment; Female; Follow-Up Studies; Glaucoma, Neovascular; | 1998 |
Iris neovascularization following branch retinal artery occlusion.
Topics: Aged; Anterior Eye Segment; Blood Flow Velocity; Carotid Artery, Common; Carotid Stenosis; Fluoresce | 1998 |
Increased interleukin-6 in aqueous humor of neovascular glaucoma.
Topics: Aged; Aqueous Humor; Enzyme-Linked Immunosorbent Assay; Female; Glaucoma, Neovascular; Humans; Inter | 1999 |
The 30-Hz flicker cone ERG for monitoring the early course of central retinal vein occlusion.
Topics: Aged; Electroretinography; Female; Humans; Iris; Male; Middle Aged; Neovascularization, Pathologic; | 2000 |
[Development of neovascularization of the optic papilla, retina and iris. Dependence on site and extent of retinal ischemia].
Topics: Diabetic Retinopathy; Fluorescein Angiography; Humans; Iris; Ischemia; Neovascularization, Pathologi | 2000 |
Photopic 30 Hz flicker ERG as a predictor for rubeosis in central retinal vein occlusion.
Topics: Adult; Aged; Electroretinography; Female; Humans; Iris; Male; Middle Aged; Neovascularization, Patho | 2001 |
Nine year follow-up study of morbidity and mortality in retinal vein occlusion.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cause of Death; Comorbidity; Diabetes Melli | 2000 |
The development and management of neovascular glaucoma.
Topics: Adult; Aged; Aged, 80 and over; Cell Count; Diabetic Retinopathy; Endothelium, Corneal; Female; Fluo | 1990 |
Combined branch retinal artery and central retinal vein obstruction.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorescein Angiography; Fundus Oculi; Humans; Iris; Light C | 1990 |
Spontaneous dural carotid-cavernous fistula with central retinal vein occlusion and iris neovascularization.
Topics: Arteriovenous Fistula; Carotid Artery Diseases; Cavernous Sinus; Diagnosis, Differential; Female; Fl | 1991 |
Neovascular response in ischaemic central retinal vein occlusion after panretinal photocoagulation.
Topics: Aged; Aged, 80 and over; Female; Fluorescein Angiography; Humans; Iris; Ischemia; Light Coagulation; | 1991 |
Electroretinogram b-wave implicit time and b/a wave ratio as a function of intensity in central retinal vein occlusion.
Topics: Aged; Electroretinography; Humans; Iris; Neovascularization, Pathologic; Predictive Value of Tests; | 1991 |
Phthalocyanine photodynamic therapy of experimental iris neovascularization.
Topics: Aluminum; Animals; Corneal Diseases; Disease Models, Animal; Endothelium, Corneal; Fluorescein Angio | 1991 |
Differential diagnosis of spontaneous hyphema associated with central retinal vein occlusion.
Topics: Aged; Diagnosis, Differential; Glaucoma; Humans; Hyphema; Iris; Male; Neovascularization, Pathologic | 1986 |
[Experiences with a modified, intraocular pressure-reducing excision of the ciliary body].
Topics: Ciliary Body; Cryosurgery; Diabetic Retinopathy; Follow-Up Studies; Glaucoma; Humans; Intraocular Pr | 1986 |
Following up patients with central retinal vein occlusion.
Topics: Electroretinography; Follow-Up Studies; Humans; Iris; Neovascularization, Pathologic; Retinal Vein O | 1988 |
Neovascularization in central retinal vein occlusion: electroretinographic findings.
Topics: Electroretinography; Fluorescein Angiography; Humans; Iris; Neovascularization, Pathologic; Retinal | 1988 |
Early electroretinography in unilateral central retinal vein occlusion as a predictor of rubeosis iridis.
Topics: Electroretinography; Forecasting; Humans; Iris; Lighting; Neovascularization, Pathologic; Retinal Ve | 1988 |
Importance of medical treatment in retinal vein occlusion.
Topics: Adult; Aged; Combined Modality Therapy; Female; Humans; Iris; Male; Neovascularization, Pathologic; | 1987 |
Central retinal vein occlusion and iris neovascularization hemorrhage.
Topics: Humans; Hyphema; Iris; Male; Middle Aged; Neovascularization, Pathologic; Retinal Vein Occlusion | 1988 |
[Retinal cryocoagulation in rubeosis iridis].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cryosurgery; Diabetic Retinopathy; Follow-Up Studies; Hu | 1988 |
Cellular mechanisms of iris neovascularization secondary to retinal vein occlusion.
Topics: Animals; Autoradiography; Biomechanical Phenomena; Fluorescein Angiography; Fundus Oculi; Iris; Maca | 1989 |
Electroretinogram parameters at presentation as predictors of rubeosis in central retinal vein occlusion patients.
Topics: Aged; Data Interpretation, Statistical; Electroretinography; Female; Humans; Iris; Iris Diseases; Ma | 1989 |
Severe ischemic process in a young man with central retinal vein occlusion.
Topics: Adult; Atrophy; Fluorescein Angiography; Glaucoma, Neovascular; Humans; Intraocular Pressure; Iris; | 1988 |